Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:27:50.046Z.
Calculation as of: 2026-10-06T21:27:50.046Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2828d634106ca83d862f06563bd3207250bf68b7c28fdcde625e8fc73480fe95
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.62B
EBITDA Yield
1.77%
TTM Avg
1.16%
3Y Avg
1.16%
5Y Avg
1.16%
Market Cap
$1.63B
EBITDA Yield
14.78%
TTM Avg
10.69%
3Y Avg
8.08%
5Y Avg
6.99%
Market Cap
$1.59B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.57B
EBITDA Yield
N/A
TTM Avg
4.60%
3Y Avg
4.60%
5Y Avg
4.60%
Market Cap
$1.54B
EBITDA Yield
N/A
TTM Avg
1.78%
3Y Avg
1.78%
5Y Avg
1.78%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocular Therapeutix, Inc. (OCUL) | $1.61B | N/A | N/A | N/A | N/A |
| Septerna Inc (SEPN)vs › | $1.61B | N/A | N/A | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 9.30% | 6.49% | 5.12% | 4.30% |
| uniQure N.V. (QURE)vs › | $1.60B | N/A | 65.74% | 64.80% | 64.80% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | 1.77% | 1.16% | 1.16% | 1.16% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 14.78% | 10.69% | 8.08% | 6.99% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | N/A | N/A | N/A | N/A |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | N/A | 4.60% | 4.60% | 4.60% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | N/A | 1.78% | 1.78% | 1.78% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 20.41% | 5.47% | 8.19% | 12.57% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
